{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T17:05:24Z","timestamp":1773335124863,"version":"3.50.1"},"reference-count":12,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:00:00Z","timestamp":1773273600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"DOI":"10.3389\/fmed.2026.1813324","type":"journal-article","created":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T05:27:23Z","timestamp":1773293243000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Editorial: Exploiting biomarkers for targeted therapies in acute myeloid leukemia"],"prefix":"10.3389","volume":"13","author":[{"given":"Diego","family":"Carbonell","sequence":"first","affiliation":[{"name":"Department of Hematology, Gregorio Mara\u00f1\u00f3n General University Hospital","place":["Madrid, Spain"]},{"name":"Gregorio Mara\u00f1\u00f3n Health Research Institute (IiSGM)","place":["Madrid, Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood."},{"key":"B2","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1002\/ajh.26822","article-title":"Acute myeloid leukemia: 2023 update on diagnosis, risk-stratification, and management","volume":"98","author":"Shimony","year":"2023","journal-title":"Am J Hematol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1038\/s41420-022-01193-0","article-title":"The genesis and evolution of acute myeloid leukemia stem cells in the microenvironment: from biology to therapeutic targeting","volume":"8","author":"Chen","year":"2022","journal-title":"Cell Death Discov."},{"key":"B4","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1038\/s41375-022-01789-6","article-title":"Single-cell analysis reveals the chemotherapy-induced cellular reprogramming and novel therapeutic targets in relapsed\/refractory acute myeloid leukemia","volume":"37","author":"Li","year":"2023","journal-title":"Leukemia."},{"key":"B5","doi-asserted-by":"publisher","first-page":"25060","DOI":"10.1038\/s41598-024-75429-7","article-title":"Modelling post-chemotherapy stem cell dynamics in the bone marrow niche of AML patients","volume":"14","author":"Zhu","year":"2024","journal-title":"Sci Rep."},{"key":"B6","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1002\/ajh.27584","article-title":"Treatment of relapsed\/refractory AML-novel treatment options including immunotherapy","volume":"100","author":"Moore","year":"2025","journal-title":"Am J Hematol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1275251","DOI":"10.3389\/fonc.2024.1275251","article-title":"Therapeutic biomarkers in acute myeloid leukemia: functional and genomic approaches","volume":"14","author":"Bhatia","year":"2024","journal-title":"Front Oncol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.cancergen.2024.12.006","article-title":"Omics approaches: role in acute myeloid leukemia biomarker discovery and therapy","volume":"293","author":"Shafiei","year":"2025"},{"key":"B9","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s10238-025-01764-2","article-title":"Targeting acute myeloid leukemia through antibody engineering: innovations in immunotherapy and combination regimens","volume":"25","author":"Soleimani Samarkhazan","year":"2025","journal-title":"Clin Exp Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1038\/s41568-024-00737-z","article-title":"Cancer drug-tolerant persister cells: from biological questions to clinical opportunities","volume":"24","author":"Russo","year":"2024","journal-title":"Nat Rev Cancer."},{"key":"B11","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/s41375-021-01350-x","article-title":"Catch me if you can: how AML and its niche escape immunotherapy","volume":"36","author":"Tettamanti","year":"2022","journal-title":"Leukemia."},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2025031480.","article-title":"2025 Update on MRD in acute myeloid leukemia: a consensus document from the ELN-DAVID MRD working party","author":"Cloos","year":"2025","journal-title":"Blood."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1813324\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T05:27:24Z","timestamp":1773293244000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1813324\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,12]]},"references-count":12,"alternative-id":["10.3389\/fmed.2026.1813324"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1813324","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,12]]},"article-number":"1813324"}}